Molecular Profile Detail

Profile Name BRCA2 mutant
Gene Variant Detail

BRCA2 mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRCA2 mutant ovarian cancer sensitive Rucaparib Guideline Actionable Rubraca (rucaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org). detail...
BRCA2 mutant ovarian cancer sensitive Rucaparib Phase II Actionable In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934). 27002934
BRCA2 mutant ovarian cancer sensitive Rucaparib FDA approved Actionable In a retrospective analysis of two Phase II trials (ARIEL 2 and Study 10) that supported FDA approval, Rubraca (rucaparib) treatment resulted in an objective response rate of 54% (21/39) in high-grade ovarian cancer patients harboring BRCA2 mutations (PMID: 28751443). 28751443
BRCA2 mutant ovarian cancer sensitive Rucaparib Phase III Actionable In a Phase III trial (ARIEL3), Rubraca (rucaparib) treatment resulted in significantly improved progression-free survival compared to placebo (16.6 vs 5.4 months, HR=0.23, p=0.0001) in patients with BRCA-mutant, platinum-sensitive ovarian cancer (PMID: 28916367; NCT01968213). 28916367
BRCA2 mutant Advanced Solid Tumor predicted - sensitive ABT-767 Phase I Actionable In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=14/79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150). detail...
BRCA2 mutant ovarian cancer predicted - sensitive Irinotecan + Veliparib Phase I Actionable In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236). 26842236
BRCA2 mutant fallopian tube cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 mutant pancreatic cancer predicted - sensitive Rucaparib Phase II Actionable In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19) and a disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)). detail...
BRCA2 mutant ovarian cancer predicted - sensitive Niraparib Phase III Actionable In a Phase III trial (NOVA), maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299; NCT01847274). 27717299
BRCA2 mutant ovarian cancer sensitive Olaparib Guideline Actionable Lynparza (olaparib) is included in the guidelines as recurrence therapy for ovarian cancer patients harboring BRCA1/2 germline mutations (NCCN.org). detail...
BRCA2 mutant ovarian cancer sensitive Olaparib Phase III Actionable In a Phase III trial, ovarian cancer patients who are platinum-sensitive and relapsed and harbor either mutant BRCA1 or mutant BRCA2 demonstrated a greater progression-free survival (19.1 mo vs 5.5 mo) when treated with Lynparza (olaparib) tablets as maintenance therapy compared to placebo (PMID: 28754483; NCT01874353). 28754483
BRCA2 mutant ovarian cancer sensitive Olaparib Preclinical - Pdx Actionable In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693). 21097693
BRCA2 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 mutant ovarian cancer sensitive Olaparib FDA approved Actionable In a Phase II trial that supported FDA approval, treatment with Lynparza (olaparib) resulted in a tumor response rate of 34% (n=137) and median duration of response of 7.9 months in ovarian cancer patients harboring germline BRCA1/2 mutations that had received 3 or more lines of chemotherapy (PMID: 26187614, PMID: 25366685; NCT01078662). 26187614 25366685
BRCA2 mutant peritoneum cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (SOLO1) that supported FDA approval, Lynparza (olaparib) maintenance therapy resulted in significantly improved time to first subsequent therapy or death (51.8 vs 15.1 months, HR=0.30, p<0.0001) and progression-free survival (HR=0.30, p<0.0001) compared to placebo in patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer, who had a complete or partial clinical response after platinum-based chemotherapy (PMID: 30345884; NCT01844986). 30345884
BRCA2 mutant breast cancer predicted - sensitive Veliparib + Carboplatin Phase I Actionable In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)). detail...
BRCA2 mutant pancreatic cancer sensitive Talazoparib Phase I Actionable In a Phase I trial, Talazoparib (BMN-673) treatment in pancreatic cancer patients resulted in four patients with a clinical benefit including a partial response in one patient harboring a BRCA2 mutation (PMID: 28242752). 28242752
BRCA2 mutant ovarian carcinoma no benefit Bevacizumab + Carboplatin + Paclitaxel Clinical Study Actionable In a clinical study, ovarian carcinoma patients harboring a mutation in either BRCA1, BRCA2, or another homologous recombination repair (HRR) gene did not demonstrate a significant difference in progression free survival when Avastin (bevacizumab) was added to the combined platinum therapy, Platinol (carboplatin) and Taxol (paclitaxel), versus the platinum therapy with placebo, suggesting HRR gene mutations do not impact the effect of Avastin (bevacizumab) (PMID: 29191972). 29191972
BRCA2 mutant ovarian cancer predicted - sensitive Pamiparib Phase I Actionable In a Phase I trial, BGB-290 treatment resulted in an improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723). detail...
BRCA2 mutant breast cancer predicted - sensitive Talazoparib Phase I Actionable In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14), including one patient with a complete response and six patients with a partial response, and resulted in a median progression free survival of 34.6 weeks (PMID: 28242752). 28242752
BRCA2 mutant Her2-receptor negative breast cancer predicted - sensitive Cisplatin + Veliparib + Vinorelbine Phase I Actionable In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247). 26801247
BRCA2 mutant prostate cancer sensitive Veliparib Phase II Actionable In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)). detail...
BRCA2 mutant Her2-receptor negative breast cancer sensitive Olaparib FDA approved Actionable In a Phase III trial (OlympiAD) that supported FDA approval, Lynparza (olaparib) treatment resulted in significantly improved median progression-free survival (7.0 vs 4.2 months, HR=0.58, p<0.001) and higher response rate (59.9% vs 28.8%) compared to standard chemotherapy in ERBB2 (HER2)-negative breast cancer patients harboring a germline BRCA mutation (PMID: 28578601; NCT02000622). 28578601
BRCA2 mutant ovarian cancer predicted - sensitive Talazoparib Phase I Actionable In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752). 28242752
BRCA2 mutant triple-receptor negative breast cancer decreased response Talazoparib Phase I Actionable In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752). 28242752
BRCA2 mutant breast cancer sensitive Olaparib Phase II Actionable In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467). 20609467
BRCA2 mutant pancreatic cancer not applicable N/A Guideline Risk Factor Germline BRCA1/2 mutations are associated with increased risk of developing and early onset of pancreatic cancer (NCCN.org). detail...
BRCA2 mutant Advanced Solid Tumor predicted - sensitive CX-5461 Phase I Actionable In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01945775 Phase III Gemcitabine Capecitabine Vinorelbine Talazoparib Eribulin A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Active, not recruiting
NCT02953457 Phase Ib/II MEDI4736 + Olaparib + Tremelimumab Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation Recruiting
NCT02034916 Phase II Talazoparib A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) Completed
NCT03414047 Phase II Prexasertib A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Recruiting
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Recruiting
NCT03413995 Phase II Rucaparib Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) Recruiting
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT03025035 Phase II Pembrolizumab Pembrolizumab in Advanced BRCA-mutated Breast Cancer Recruiting
NCT02203513 Phase II Prexasertib Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk Recruiting
NCT03375307 Phase II Olaparib Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects Recruiting
NCT01847274 Phase III Niraparib A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer Completed
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting
NCT02401347 Phase II Talazoparib Talazoparib Beyond BRCA (TBB) Trial Recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Olaparib Selumetinib Ensartinib Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas Recruiting
NCT01482715 Rucaparib A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Active, not recruiting
NCT02314156 Phase II Telapristone Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Active, not recruiting
NCT02983799 Phase II Olaparib Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status Recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02184195 Phase III Olaparib Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Active, not recruiting
NCT03432676 Phase II Epacadostat + Pembrolizumab Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) Withdrawn
NCT03641755 Phase Ib/II Olaparib + Sapacitabine A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer Recruiting
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Active, not recruiting
NCT03012321 Phase II Abiraterone + Prednisone + Olaparib Abiraterone + Prednisone Olaparib Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects Recruiting
NCT02873975 Phase II Prexasertib A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Recruiting
NCT03801369 Phase II Durvalumab + Olaparib Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT02358200 Phase I Paclitaxel + Carboplatin Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Active, not recruiting
NCT03704467 Phase II Bevacizumab + Carboplatin + Gemcitabine + Paclitaxel Avelumab + Carboplatin + VX-970 Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine Diphosphate Ribose [ADP]-Ribose) Polymerase Inhibitor (PARPi)-Resistant Recurrent Ovarian Cancer Recruiting
NCT01905592 Phase III Niraparib A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients Active, not recruiting
NCT03337087 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib Phosphate in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting
NCT02734004 Phase Ib/II Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02326844 Phase II Talazoparib BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment Terminated
NCT03317405 Phase I Z-endoxifen HCl Z-Endoxifen Hydrochloride in Treating Patients With Stage 0-III Breast Cancer Undergoing Surgery Recruiting
NCT01434316 Phase I Veliparib + Dinaciclib Veliparib + Dinaciclib + carboplatin Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors Recruiting
NCT02849496 Phase II Atezolizumab Atezolizumab + Veliparib Veliparib Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer Recruiting
NCT03742895 Phase II Olaparib Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002) Recruiting
NCT02163694 Phase III Veliparib Paclitaxel + Carboplatin A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Active, not recruiting
NCT02595905 Phase I Cisplatin Veliparib Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer Recruiting
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Active, not recruiting
NCT02677038 Phase II Olaparib Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting
NCT01844986 Phase III Olaparib Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Active, not recruiting
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Recruiting
NCT02393794 Phase Ib/II Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Recruiting
NCT02571725 Phase Ib/II Tremelimumab Olaparib PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting
NCT03286842 Phase III Olaparib To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. Active, not recruiting
NCT03565991 Phase II Avelumab + Talazoparib Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors Recruiting
NCT02392676 Phase III Olaparib Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations Withdrawn
NCT02576444 Phase II MK-1775 + Olaparib Olaparib Olaparib + Vistusertib AZD5363 + Olaparib OLAParib COmbinations Recruiting
NCT03552471 Phase I Mirvetuximab Soravtansine + Rucaparib Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting
NCT03402841 Phase III Olaparib Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients (OPINION) Recruiting
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001) Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT03061188 Phase I Veliparib + Nivolumab Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes Recruiting
NCT02987543 Phase III Olaparib Enzalutamide Abiraterone Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Active, not recruiting
NCT02158507 Phase I Lapatinib + Veliparib Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer Active, not recruiting
NCT01489865 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Veliparib ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Active, not recruiting
NCT02286687 Phase II Talazoparib Phase II Study of BMN 673 Recruiting
NCT03344965 Phase II Olaparib Olaparib In Metastatic Breast Cancer Recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Nivolumab + Ipilimumab Vemurafenib + Cobimetinib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT02042378 Phase II Rucaparib A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed
NCT03448718 Phase II Olaparib Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting
NCT01874353 Phase III Olaparib Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Active, not recruiting
NCT02476968 FDA approved Olaparib To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer Active, not recruiting
NCT02465060 Phase II Dabrafenib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Binimetinib Adavosertib Osimertinib Trastuzumab Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib trastuzumab emtansine Larotrectinib Pertuzumab Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT03318445 Phase I Rucaparib Irinotecan + Rucaparib Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Recruiting
NCT03462342 Phase II AZD6738 + Olaparib Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI) Recruiting
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn
NCT03499353 Phase II Talazoparib Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer Recruiting
NCT02317874 Phase I Paclitaxel + Carboplatin Talazoparib PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT02561832 Phase I Cyclophosphamide Olaparib Carboplatin A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer Terminated
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Available
NCT02446600 Phase III Paclitaxel Doxorubicin Gemcitabine Carboplatin Olaparib Cediranib Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT03432897 Phase II Olaparib BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes (337) Recruiting
NCT03428802 Phase II Pembrolizumab Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability Recruiting
NCT01585805 Phase II Veliparib Gemcitabine + Cisplatin Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer Active, not recruiting
NCT02282345 Phase II Talazoparib Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation Active, not recruiting
NCT01506609 Phase II Veliparib + Temozolomide Carboplatin + Etoposide + Veliparib Paclitaxel + Carboplatin The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer Active, not recruiting
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT01525589 Phase II Lurbinectedin A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Completed